Please use symbol entry at top right of page to search

Anti-CD20 Monoclonal Antibodies (mABs) Market size to increase by USD 9.05 Bn | 9.0% YOY growth expected in 2022 | Technavio

NEW YORK, May 24, 2022 /PRNewswire/ -- The global anti-CD20 monoclonal antibodies (mABs) market size is expected to increase by USD 9.05 billion between 2021 and 2026, expanding at a CAGR of 9.81% during the forecast period. Also, the report expects the market to observe a YOY growth of 9% in 2022. The report provides a detailed analysis of the recent developments, new product launches, major revenue-generating segments, and market behavior across geographies. The market will observe maximum growth in North America. The high incidence and prevalence of hematologic malignancies such as NHL are creating significant demand for anti-CD20 monoclonal antibodies in the region.

Technavio has announced its latest market research report titled Anti-CD20 Monoclonal Antibodies (mABs) Market by Product and Geography - Forecast and Analysis 2022-2026

View Our Sample Report to know more about the report coverage and growth opportunities across regions.

The increased use of combination therapies is one of the major factors driving the growth of the market. In addition, factors such as high target affinity and specificity of anti-CD20 mABs and strong pipeline and recent approvals will have a positive impact on the market growth. However, factors such as the adverse effects of anti-CD20 mABs, complexity in the development of anti-CD20 monoclonal antibodies, and the emergence of alternative therapies will hamper the market growth.

Anti-CD20 Monoclonal Antibodies (mABs) Market: Product Landscape

  • Based on the product, the market is analyzed across segments such as oncology, neurology, and immunology.
  • The oncology segment will generate maximum revenue in the market through the forecast period.
  • The growth of the oncology segment can be attributed to the availability of anti-CD20 mAbs for treating high prevalent oncology indications.
  • Also, the high incidence and prevalence of cancer are propelling the growth of the oncology segment.

Anti-CD20 Monoclonal Antibodies (mABs) Market: Geographic Landscape

  • By geography, North America is going to have a lucrative growth during the forecast period.
  • About 69% of the market's overall growth is expected to originate from North America.
  • The growth of the market in North America is driven by recent approvals of RITUXAN combinations in the US.
  • Also, the continuous demand for OCREVUS, led by the increasing incidence and relapsed cases of multiple sclerosis is contributing to the growth of the regional market.
  • The US and Canada are the key markets for the anti-CD20 monoclonal antibodies (mAbs) market in North America.

Identify other potential growth segments and regions in the global rough terrain lift truck market. Download a Report Sample

Companies Covered:

The global anti-CD20 monoclonal antibodies (mAbs) market is fragmented. The market has several approved molecules for the treatment of chronic diseases. Vendors in the market are focusing on the development of anti-CD20 monoclonal antibodies (mAbs) to treat chronic diseases such as cancer and rheumatoid arthritis. Technavio identifies the following as the key players in the market.

  • Acrotech Biopharma
  • Amgen Inc.
  • AstraZeneca Plc
  • Celltrion Healthcare Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fosun International Ltd.
  • Genmab AS
  • IGM Biosciences Inc.
  • JSC BIOCAD
  • LFB SA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Spectrum Pharmaceuticals Inc.
  • TG Therapeutics Inc.
  • United BioPharma Inc.
  • ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.

What our reports offer:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers market data for 2021, 2022, until 2026
  • Market trends (drivers, opportunities, threats, challenges, investment opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

View Our Report Sample for more highlights on the vendor landscape.

Related Reports:

  • Cancer Biologics Market by Product and Geography - Forecast and Analysis 2022-2026
  • Antinuclear Antibody Test Market by End-user and Geography - Forecast and Analysis 2022-2026

Anti-CD20 Monoclonal Antibodies (mABs) Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 9.81%

Market growth 2022-2026

USD 9.05 billion

Market structure

Fragmented

YoY growth (%)

9.0

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 69%

Key consumer countries

US, Canada, Mexico, Germany, and UK

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Acrotech Biopharma, Amgen Inc., AstraZeneca Plc, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents:

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
    • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
    • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
    • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
    • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
    • Exhibit 17: Five forces analysis - Comparison between2021 and 2026
  • 4.2 Bargaining power of buyers
    • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers
    • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
    • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
    • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
    • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
  • 4.7 Market condition
    • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

  • 5.1 Market segments
    • Exhibit 24: Chart on Product - Market share 2021-2026 (%)
    • Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
  • 5.2 Comparison by Product
    • Exhibit 26: Chart on Comparison by Product
    • Exhibit 27: Data Table on Comparison by Product
  • 5.3 Oncology - Market size and forecast 2021-2026
    • Exhibit 28: Chart on Oncology - Market size and forecast 2021-2026 ($ million)
    • Exhibit 29: Data Table on Oncology - Market size and forecast 2021-2026 ($ million)
    • Exhibit 30: Chart on Oncology - Year-over-year growth 2021-2026 (%)
    • Exhibit 31: Data Table on Oncology - Year-over-year growth 2021-2026 (%)
  • 5.4 Neurology - Market size and forecast 2021-2026
    • Exhibit 32: Chart on Neurology - Market size and forecast 2021-2026 ($ million)
    • Exhibit 33: Data Table on Neurology - Market size and forecast 2021-2026 ($ million)
    • Exhibit 34: Chart on Neurology - Year-over-year growth 2021-2026 (%)
    • Exhibit 35: Data Table on Neurology - Year-over-year growth 2021-2026 (%)
  • 5.5 Immunology - Market size and forecast 2021-2026
    • Exhibit 36: Chart on Immunology - Market size and forecast 2021-2026 ($ million)
    • Exhibit 37: Data Table on Immunology - Market size and forecast 2021-2026 ($ million)
    • Exhibit 38: Chart on Immunology - Year-over-year growth 2021-2026 (%)
    • Exhibit 39: Data Table on Immunology - Year-over-year growth 2021-2026 (%)
  • 5.6 Market opportunity by Product
    • Exhibit 40: Market opportunity by Product ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
    • Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
    • Exhibit 42: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparison
    • Exhibit 44: Chart on Geographic comparison
    • Exhibit 45: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
    • Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
    • Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
    • Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
    • Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
    • Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
    • Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
    • Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
    • Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
    • Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
    • Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
    • Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
    • Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
    • Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
    • Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
    • Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 US - Market size and forecast 2021-2026
    • Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
    • Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
    • Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
    • Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.8 Canada - Market size and forecast 2021-2026
    • Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million)
    • Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
    • Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%)
    • Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • 7.9 Mexico - Market size and forecast 2021-2026
    • Exhibit 70: Chart on Mexico - Market size and forecast 2021-2026 ($ million)
    • Exhibit 71: Data Table on Mexico - Market size and forecast 2021-2026 ($ million)
    • Exhibit 72: Chart on Mexico - Year-over-year growth 2021-2026 (%)
    • Exhibit 73: Data Table on Mexico - Year-over-year growth 2021-2026 (%)
  • 7.10 Germany - Market size and forecast 2021-2026
    • Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
    • Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
    • Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
    • Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
  • 7.11 UK - Market size and forecast 2021-2026
    • Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ million)
    • Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ million)
    • Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%)
    • Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity by geography
    • Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
    • Exhibit 83: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
    • Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
    • Exhibit 85: Overview on factors of disruption
  • 9.4 Industry risks
    • Exhibit 86: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
    • Exhibit 87: Vendors covered
  • 10.2 Market positioning of vendors
    • Exhibit 88: Matrix on vendor position and classification
  • 10.3 Acrotech Biopharma
    • Exhibit 89: Acrotech Biopharma - Overview
    • Exhibit 90: Acrotech Biopharma - Product / Service
    • Exhibit 91: Acrotech Biopharma - Key offerings
  • 10.4 Amgen Inc.
    • Exhibit 92: Amgen Inc. - Overview
    • Exhibit 93: Amgen Inc. - Product / Service
    • Exhibit 94: Amgen Inc. - Key offerings
  • 10.5 Celltrion Healthcare Co. Ltd.
    • Exhibit 95: Celltrion Healthcare Co. Ltd. - Overview
    • Exhibit 96: Celltrion Healthcare Co. Ltd. - Product / Service
    • Exhibit 97: Celltrion Healthcare Co. Ltd. - Key offerings
  • 10.6 F. Hoffmann La Roche Ltd.
    • Exhibit 98: F. Hoffmann La Roche Ltd. - Overview
    • Exhibit 99: F. Hoffmann La Roche Ltd. - Business segments
    • Exhibit 100: F. Hoffmann La Roche Ltd. - Key news
    • Exhibit 101: F. Hoffmann La Roche Ltd. - Key offerings
    • Exhibit 102: F. Hoffmann La Roche Ltd. - Segment focus
  • 10.7 IGM Biosciences Inc.
    • Exhibit 103: IGM Biosciences Inc. - Overview
    • Exhibit 104: IGM Biosciences Inc. - Product / Service
    • Exhibit 105: IGM Biosciences Inc. - Key offerings
  • 10.8 LFB SA
    • Exhibit 106: LFB SA - Overview
    • Exhibit 107: LFB SA - Product / Service
    • Exhibit 108: LFB SA - Key offerings
  • 10.9 Novartis AG
    • Exhibit 109: Novartis AG - Overview
    • Exhibit 110: Novartis AG - Business segments
    • Exhibit 111: Novartis AG - Key offerings
    • Exhibit 112: Novartis AG - Segment focus
  • 10.10 Pfizer Inc.
    • Exhibit 113: Pfizer Inc. - Overview
    • Exhibit 114: Pfizer Inc. - Product / Service
    • Exhibit 115: Pfizer Inc. - Key news
    • Exhibit 116: Pfizer Inc. - Key offerings
  • 10.11 Regeneron Pharmaceuticals Inc.
    • Exhibit 117: Regeneron Pharmaceuticals Inc. - Overview
    • Exhibit 118: Regeneron Pharmaceuticals Inc. - Product / Service
    • Exhibit 119: Regeneron Pharmaceuticals Inc. - Key offerings
  • 10.12 TG Therapeutics Inc.
    • Exhibit 120: TG Therapeutics Inc. - Overview
    • Exhibit 121: TG Therapeutics Inc. - Product / Service
    • Exhibit 122: TG Therapeutics Inc. - Key offerings

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
    • Exhibit 123: Inclusions checklist
    • Exhibit 124: Exclusions checklist
  • 11.3 Currency conversion rates for US$
    • Exhibit 125: Currency conversion rates for US$
  • 11.4 Research methodology
    • Exhibit 126: Research methodology
    • Exhibit 127: Validation techniques employed for market sizing
    • Exhibit 128: Information sources
  • 11.5 List of abbreviations
    • Exhibit 129: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Technavio (PRNewsfoto/Technavio)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/anti-cd20-monoclonal-antibodies-mabs-market-size-to-increase-by-usd-9-05-bn--9-0-yoy-growth-expected-in-2022--technavio-301552951.html

SOURCE Technavio

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.